INTRODUCTION
respiratory viral infections, deaths
CORONAVIRUS DISEASE 2019, RESPIRATORY VIRAL INFECTION
Coronavirus disease 2019 (COVID-19) remains a major global public health challenge, with over 620 million cases reported and more than 6.5 million deaths worldwide as of October 2022 (Several COVID-19 vaccines, neutralizing monoclonal antibody therapies, and direct-acting antivirals (DAAs) are now available (There are currently 2 DAAs approved in Europe and the United States for treating adult ambulatory patients with COVID-19 at increased risk for progressing to severe COVID-19: nirmatrelvir, a protease inhibitor administered orally with ritonavir (In clinical trials of monoclonal antibodies and DAAs approved for treatment of COVID-19, the positive clinical outcomes observed have typically correlated with viral load reduction in the nasopharyngeal space, and indeed, nasopharyngeal viral load reduction has been widely used as a measure of antiviral activity in the development of antivirals for respiratory viral infections (Bemnifosbuvir (AT-527), the hemisulfate salt of AT-511, is an orally administered guanosine nucleotide analog double prodrug with potent Here, we report the antiviral activity, safety, efficacy, and pharmacokinetic results from a phase 2 study of bemnifosbuvir versus placebo in ambulatory patients with mild or moderate COVID-19.